BridgeMD
New treatment option for Posttraumatic Stress Disorder
Official title Multicenter iTBS Neuromodulation for PTSD Treatment
ClinicalTrials.gov ID: NCT06434766
What this study is testing
- What it's testing
- The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social/occupation functioning and functional connectivity of the brain.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Aged between 18 to 65 years old
- Right handedness
- Have a diagnosis of PTSD meeting DSM-5 criteria
- CAPS-5 score\>35
- Under stable medication for at least four weeks
You likely can't join if
- Current (or past if appropriate) significant neurological or medical disorder, or lifetime history of 1) seizure disorder; 2) primary or secondary...
- Primary psychotic disorder, bipolar I disorder, major depressive disorder, or personality disorders
- Lifetime history of attempted suicide or HAMD-17 suicide item (item 3) ≥ 3 points
- Implanted device (deep brain stimulation) or metal in the brain; a pacemaker, extensive dental work, or any magnetic metal implants and upper body...
- Previous experience of rTMS
- Pregnancy/lactation, or planning to become pregnant during the study
See the full eligibility criteria
- Aged between 18 to 65 years old
- Right handedness
- Have a diagnosis of PTSD meeting DSM-5 criteria
- CAPS-5 score\>35
- Under stable medication for at least four weeks
- Capable of independently reading and understanding study materials and providing informed consent.
- Current (or past if appropriate) significant neurological or medical disorder, or lifetime history of 1) seizure disorder; 2) primary or secondary CNS tumors; 3) stroke; or 4) cerebral aneurysm.
- Primary psychotic disorder, bipolar I disorder, major depressive disorder, or personality disorders
- Lifetime history of attempted suicide or HAMD-17 suicide item (item 3) ≥ 3 points
- Implanted device (deep brain stimulation) or metal in the brain; a pacemaker, extensive dental work, or any magnetic metal implants and upper body tattoos if choose to do fMRI
- Previous experience of rTMS
- Pregnancy/lactation, or planning to become pregnant during the study
- Current under psychological or other physical treatments
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
- Hangzhou, Zhejiang, China
- Ningbo, Zhejiang, China
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China; Hangzhou, Zhejiang, China; Ningbo, Zhejiang, China; Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.